文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性乳腺癌患者中64Cu-DOTA-曲妥珠单抗的肿瘤摄取

Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.
PubMed 文献 · J Nucl Med · 2017-06-21

本研究在转移性乳腺癌(MBC)女性患者中,比较PET/CT测量的64Cu-DOTA-曲妥珠单抗肿瘤摄取与基于免疫组化(IHC)的HER2状态分类。18例患者中11例HER2阳性、7例HER2阴性;第1天和第2天HER2阳性患者的中位平均SUVmax分别为6.6和6.8 g/mL,HER2阴性患者分别为3.7和4.3 g/mL(P<0.005)。结论认为注射后1天摄取与HER2状态强相关,提示结合HER2,但两组分布重叠且HER2阳性组个体间变异更大。

要点

  • HER2阳性患者第1天和第2天中位平均SUVmax分别为6.6和6.8 g/mL。
  • HER2阴性患者第1天和第2天中位平均SUVmax分别为3.7和4.3 g/mL(P<0.005)。
  • 两组平均SUVmax分布重叠,HER2阳性组个体间变异更大。

核心结论

  • 注射后1天,64Cu-DOTA-曲妥珠单抗在MBC中的摄取与患者HER2状态强相关,并提示与HER2结合。
  • HER2阳性患者内及患者间的变异,以及HER2阳性与HER2阴性组间的重叠,提示64Cu-DOTA-曲妥珠单抗PET/CT可能在优化含曲妥珠单抗的治疗中发挥作用。

研究设计与样本

  • 活检确认的MBC女性患者,且至少2个月未接受曲妥珠单抗治疗,接受完整分期包括18F-FDG PET/CT。
  • 根据活检肿瘤组织的荧光原位杂交(FISH)补充免疫组化结果,将患者分类为HER2阳性或HER2阴性。
  • 18例患者接受64Cu-DOTA-曲妥珠单抗注射,其中16例在注射前接受曲妥珠单抗输注(45 mg)。
  • 在64Cu-DOTA-曲妥珠单抗注射后21-25小时(第1天)和47-49小时(第2天)进行PET/CT。
  • 测量突出病灶的放射性摄取作为SUVmax,计算患者内平均SUVmax(<SUVmax>pt),比较HER2阳性和HER2阴性患者。

主要发现

  • 11例女性为HER2阳性(8例免疫组化3+;3例免疫组化2+/FISH扩增),7例为HER2阴性(3例免疫组化2+/FISH未扩增;4例免疫组化1+)。
  • HER2阳性患者第1天和第2天中位<SUVmax>pt分别为6.6和6.8 g/mL,HER2阴性患者分别为3.7和4.3 g/mL(P<0.005)。
  • <SUVmax>pt的分布在两组间重叠。
  • HER2阳性疾病的患者间变异大于HER2阴性疾病(第1天和第2天P<0.005和0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classification of human epidermal growth factor receptor 2 (HER2) status in women with metastatic breast cancer (MBC). Methods: Women with biopsy-confirmed MBC and not given trastuzumab for 2 mo or more underwent complete staging, including 18F-FDG PET/CT. Patients were classified as HER2-positive (HER2+) or -negative (HER2-) based on fluorescence in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue. Eighteen patients underwent 64Cu-DOTA-trastuzumab injection, preceded in 16 cases by trastuzumab infusion (45 mg). PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h after 64Cu-DOTA-trastuzumab injection. Radiolabel uptake in prominent lesions was measured as SUVmax Average intrapatient SUVmax (<SUVmax>pt) was compared between HER2+ and HER2- patients. Results: Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+). Median <SUVmax>pt for day 1 and day 2 was 6.6 and 6.8 g/mL for HER 2+ and 3.7 and 4.3 g/mL for HER2- patients (P < 0.005 either day). The distributions of <SUVmax>pt overlapped between the 2 groups, and interpatient variability was greater for HER2+ than HER2- disease (P < 0.005 and 0.001, respectively, on days 1 and 2). Conclusion: By 1 d after injection, uptake of 64Cu-DOTA-trastuzumab in MBC is strongly associated with patient HER2 status and is indicative of binding to HER2. The variability within and among HER2+ patients, as well as the overlap between the HER2+ and HER2- groups, suggests a role for 64Cu-DOTA-trastuzumab PET/CT in optimizing treatments that include trastuzumab.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mortimer JE, Bading JR, Park JM, et al. Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer. J Nucl Med. 2017. PMID: 28637802. doi:10.2967/jnumed.117.193888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。